Zobrazeno 1 - 10
of 32
pro vyhledávání: '"Asgerdur Sverrisdottir"'
Autor:
Henk-Jan Guchelaar, Brian I. Rini, Lambertus A.L.M. Kiemeney, Karel K.M. Koudijs, Stefan Böhringer, Jesus García-Donas, Cristina Rodríguez-Antona, Anne Warren, Tim Eisen, Valentin Ambert, Marius T. Radu, Asgerdur Sverrisdottir, Kristin Alexiusdottir, Max Roessler, Kerstin Junker, Egbert Oosterwijk, Sita H. Vermeulen, Ron H.J. Mathijssen, Hans Gelderblom, Daniel Castellano, Epie Boven, Meta H.M. Diekstra, Jesse J. Swen, Xiaoyan Liu
Purpose: The survival of patients with clear cell metastatic renal cell carcinoma (cc-mRCC) has improved substantially since the introduction of tyrosine kinase inhibitors (TKI). With the fact that TKIs interact with immune responses, we investigated
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::427a4a1c3db2da390bddfe6a29107c30
https://doi.org/10.1158/1078-0432.c.6525825.v1
https://doi.org/10.1158/1078-0432.c.6525825.v1
Autor:
Henk-Jan Guchelaar, Brian I. Rini, Lambertus A.L.M. Kiemeney, Karel K.M. Koudijs, Stefan Böhringer, Jesus García-Donas, Cristina Rodríguez-Antona, Anne Warren, Tim Eisen, Valentin Ambert, Marius T. Radu, Asgerdur Sverrisdottir, Kristin Alexiusdottir, Max Roessler, Kerstin Junker, Egbert Oosterwijk, Sita H. Vermeulen, Ron H.J. Mathijssen, Hans Gelderblom, Daniel Castellano, Epie Boven, Meta H.M. Diekstra, Jesse J. Swen, Xiaoyan Liu
Supplementary Table S1 Selected tagging SNPs Supplementary Figure S1 Kaplan-Meier plot for overall survival by genotype of CTLA-4 rs231775 in discovery cohort (A), validation cohort (B) and combined cohort (C). Supplementary Figure S2 The association
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::01d197ea5751c6b4eef795b1e6d2dc91
https://doi.org/10.1158/1078-0432.22464837.v1
https://doi.org/10.1158/1078-0432.22464837.v1
Autor:
Helgi Birgisson, Thorvaldur Jonsson, Bjarni A. Agnarsson, Asgerdur Sverrisdottir, Lilja Dogg Gisladottir, Laufey Tryggvadottir
Publikováno v:
Læknablaðið. 106:397-402
PURPOSE As part of the implementation of quality registration in Iceland we used retrospective data to compare diagnosis and treatment of invasive breast cancer between Iceland and Sweden. MATERIALS AND METHODS Information on all patients diagnosed w
Publikováno v:
Acta oncologica (Stockholm, Sweden). 60(2)
CDK4/6 inhibitors combined with endocrine therapy (ET) have become standard treatment for endocrine receptor (ER) positive, Her-2 negative metastatic breast cancer. Three agents, palbociclib, riboc...
Autor:
Lilja Dogg, Gisladottir, Helgi, Birgisson, Bjarni A, Agnarsson, Thorvaldur, Jonsson, Laufey, Tryggvadottir, Asgerdur, Sverrisdottir
Publikováno v:
Laeknabladid. 106(9)
As part of the implementation of quality registration in Iceland we used retrospective data to compare diagnosis and treatment of invasive breast cancer between Iceland and Sweden.Information on all patients diagnosed with invasive breast cancer in I
Autor:
Asgerdur Sverrisdottir, Kenneth Villman, Johan Ahlgren, Henrik Lindman, Carl Blomqvist, Jonas Bergh, Paula Poikonen-Saksela, Per Edlund, Søren Cold, Martin Andersson, Lars Stenbygaard, Troels Bechmann, Bent Ejlertsen, Lena Tennvall Nittby
Publikováno v:
Poikonen-Saksela, P, Lindman, H, Sverrisdottir, A, Edlund, P, Villman, K, Tennvall Nittby, L, Cold, S, Bechmann, T, Stenbygaard, L, Ejlertsen, B, Andersson, M, Blomqvist, C, Bergh, J & Ahlgren, J 2020, ' Leukocyte nadir as a predictive factor for efficacy of adjuvant chemotherapy in breast cancer. Results from the prospective trial SBG 2000-1 ', Acta Oncologica, vol. 59, no. 7, pp. 825-832 . https://doi.org/10.1080/0284186X.2020.1757149
Poikonen-Saksela, P, Lindman, H, Sverrisdottir, A, Edlund, P, Villman, K, Tennvall Nittby, L, Cold, S, Bechmann, T, Stenbygaard, L, Ejlertsen, B, Andersson, M, Blomqvist, C, Bergh, J & Ahlgren, J 2020, ' Leukocyte nadir as a predictive factor for efficacy of adjuvant chemotherapy in breast cancer. Results from the prospective trial SBG 2000–1 ', Acta Oncologica, vol. 59, no. 7, pp. 825-832 . https://doi.org/10.1080/0284186X.2020.1757149
Poikonen-Saksela, P, Lindman, H, Sverrisdottir, A, Edlund, P, Villman, K, Tennvall Nittby, L, Cold, S, Bechmann, T, Stenbygaard, L, Ejlertsen, B, Andersson, M, Blomqvist, C, Bergh, J & Ahlgren, J 2020, ' Leukocyte nadir as a predictive factor for efficacy of adjuvant chemotherapy in breast cancer. Results from the prospective trial SBG 2000–1 ', Acta Oncologica, vol. 59, no. 7, pp. 825-832 . https://doi.org/10.1080/0284186X.2020.1757149
Background: Retrospective studies have suggested that chemotherapy-induced leukopenia is associated with improved recurrence-free or overall survival. The SBG 2000–1 trial was designed to verify the favorable prognosis associated with chemotherapy-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::894f834caf497ceaa864d4c9c0e130f4
https://vbn.aau.dk/da/publications/d409389a-005e-4a1a-b899-33280889fc9c
https://vbn.aau.dk/da/publications/d409389a-005e-4a1a-b899-33280889fc9c
Autor:
Bjarni A. Agnarsson, Laufey Tryggvadottir, Mats Lambe, Asgerdur Sverrisdottir, Thorvaldur Jonsson, Helgi Birgisson, Hrefna Stefansdottir, Fredrik Wärnberg, Arnar S Agustsson
Publikováno v:
Scientific Reports
Scientific Reports, Vol 10, Iss 1, Pp 1-8 (2020)
Scientific Reports, Vol 10, Iss 1, Pp 1-8 (2020)
The purpose was to review the incidence of in situ carcinoma in Iceland after initiating population-based mammography screening in 1987 and to compare management of ductal carcinoma in situ (DCIS) between Iceland and the Uppsala–Örebro region (UÖ
Autor:
Jon G. Jonasson, Stefan B. Sigurdsson, Kristrun Olafsdottir, Asgerdur Sverrisdottir, Jorunn E. Eyfjord, Oskar T. Johannsson, Holmfridur Hilmarsdottir, Laufey Tryggvadottir, Olafur A. Stefansson
Publikováno v:
JNCI Cancer Spectrum
Background Breast Cancer 1 gene (BRCA1) is known to be inactivated in breast tumors by promoter methylation. Tumor cells in patients carrying a germline mutation in BRCA1 are sensitive to cytotoxic drugs that cause DNA double strand breaks. However,
Autor:
Malgorzata K Tuxen, Carl Blomqvist, Jonas Bergh, E. H. Jacobsen, Anders Bonde Jensen, Bent Ejlertsen, N. O. Bengtsson, J. Hansen, Stig Holmberg, Lena Malmberg, Asgerdur Sverrisdottir, Martin Andersson, Kenneth Villman, Henrik Lindman, Harald Anderson, Eva Balslev, Johan Ahlgren
Publikováno v:
Swedish Breast Cancer Group (SweBCG), the Danish Breast Cancer Group (DBCG) and the Scandinavian Breast Cancer Group (SBG) 2018, ' A randomised study of tailored toxicity-based dosage of fluorouracil-epirubicin-cyclophosphamide chemotherapy for early breast cancer (SBG 2000-1) ', European journal of cancer (Oxford, England : 1990), vol. 94, pp. 79-86 . https://doi.org/10.1016/j.ejca.2018.02.016
STUDY AIM: Retrospective studies have demonstrated a worse outcome in breast cancer patients not developing leukopenia during adjuvant chemotherapy. The SBG 2000-1 is the first randomised trial designed to compare individually dosed chemotherapy with
Autor:
Aristotelis Bamias, Gero Kramer, Bohuslav Melichar, Daniel Castellano, Cora N. Sternberg, Carole Helissey, Jean-Christophe Eymard, Susan Feyerabend, Christine Theodore, Asgerdur Sverrisdottir, Ayse Ozatilgan, Christine Geffriaud-Ricouard, Johann S. de Bono, Roberto Iacovelli, Ronald de Wit, Karim Fizazi, Bertrand F. Tombal, Elizabeth M. Poole, Joan Carles, Christian Wülfing
Publikováno v:
Journal of Clinical Oncology. 38:5559-5559
5559 Background: In the CARD (NCT02485691) study, radiographic PFS (rPFS), PFS and OS were significantly improved with CBZ vs. androgen-signaling-targeted agents (ARTA; ABI or ENZ) in pts with mCRPC who had received docetaxel (DOC) and progressed wit